# Sarcoma Study of MORAb-004 Utilization: Research and Clinical Evaluation

> **NCT01574716** · PHASE2 · COMPLETED · sponsor: **Morphotek** · enrollment: 209 (actual)

## Conditions studied

- Metastatic Soft Tissue Sarcoma

## Interventions

- **DRUG:** MORAb-004
- **DRUG:** Gemcitabine
- **DRUG:** Docetaxel
- **DRUG:** Gemcitabine
- **DRUG:** Docetaxel
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01574716
- **Lead sponsor:** Morphotek
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-08-07
- **Primary completion:** 2015-08-11
- **Final completion:** 2016-08-02
- **Target enrollment:** 209 (ACTUAL)
- **Last updated:** 2019-08-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01574716

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01574716, "Sarcoma Study of MORAb-004 Utilization: Research and Clinical Evaluation". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01574716. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*